🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥POLCAGB Ph 3 neoadjuvant chemo vs neoadjuvant chemorads + chemo in locally adv GBC ➡️ closed at interim due to poor accrual 124 pts randomised ➡️ORR 74% vs 36% ➡️mOS 22mths vs 10ths Imp data - rads has a role! Nb 20% her2 amp in GBC- needs explored #ASCO25 ASCO OncoAlert

TEDOPAM - maintenance randomised phase 2 vaccine trial #PDAC Induction mFFX- Folfiri vs Folfiri+ OSE2101 (TAAs) ➡️106 pts ➡️met primary endpoint of 12mth OS>50%; ➡️But control arm mOS 17 vs vaccine arm 15mths ➡️highlights benefit maintenance approaches ASCO OncoAlert #ASCO25

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity OncoAlert #ASCO25 Ontario Institute for Cancer Research (OICR) Princess Margaret Cancer Centre

#OncoAlertTopTweet 🚨 Day 3️⃣ #ASCO25 📢 Plenary by Frank Sinicrope, MD 💥 Phase III #ATOMIC trial Adj FOLFOX ± atezo (6 mos) in stage III #MSI-H colon cancer 📈 3-yr DFS: ✅ 86.4% (atezo) vs 76.6% (ctrl) 🧮 HR 0.5 🔥 ⏳ OS immature — post-PD IO may confound ⚠️ 2 G5 TRAEs in atezo

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study - The Lancet Oncology ⁦OncoAlert⁩ #ASCO25 thelancet.com/journals/lanon…

PSMAddition trial met its primary endpoint and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer ESMO - Eur. Oncology #ASCO25 novartis.com/news/media-rel…

Congratulations to our 2nd year Hematology/Oncology fellow Louisa Liu on receiving the ASCO YIA this year for her research on the effects of time restricted eating on the gut microbiome in rectal cancer! Mentored by Dr. Figueiredo and Jun Gong. Cancer at Cedars-Sinai

So proud of Louisa Liu ‼️‼️🙌🙌 Congratulations again on your ASCO Conquer Cancer, the ASCO Foundation YIA, Dr. Liu❗️ Kamya Sankar MD Cancer at Cedars-Sinai

🗞️I received e-mails of #ASCO25 Reports of gastric/GE, pancreatic, CRC by Medical.watch ✅Thanks for giving place in the reports OncoAlert Kate Sears Gil Morgan, MD gilberto lopes Dr Joseph McCollom DO Jun Gong Dr Amol Akhade #cancer #oncology #MedX

Top #GICancer Oncologists from ASCO 2025. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #GastrointestinalCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | Sharlene Gill, MD, MPH, MBA, FASCO | Nicholas Hornstein | Arndt Vogel | Erman Akkus |

Organ preservation after TNT for LA rectal cancer (CAO/ARO/AIO-16): single-arm, phase 2 trial thelancet.com/journals/langa… Germany (N=91) cT1–2N1–2 or cT3a–dN0/N1–2 RTE+5FU CI+OXA weekly —> FOLFOX 3 cycles Day 106: 15% cCR, 38% near cCR Day 196: 37% cCR + N=2 pCR —> W&W

Huge Congratulations to Alexandra Gangi, MD my friend and hero - to uncharted new frontiers your leadership will take us! Cancer at Cedars-Sinai Cedars-Sinai

Jun Gong Cancer at Cedars-Sinai Cedars-Sinai Thank you Jun Gong Can’t do it without you!

Celebrating the inaugural graduating class of our Cancer at Cedars-Sinai heme/onc fellows Dr. Ebia Brad Gallent, MD, PhD congrats to program directors Dr. Andrew Hendifar Akil Merchant for a successful first class! We appreciate all our mentors and core faculty for our fellows Cedars-Sinai #BeverlyHills

📊 CheckMate 9DW changes the HCC landscape. In this global phase 3 RCT (n=668), nivolumab + ipilimumab demonstrated a median OS of 23.7 mo vs 20.6 mo with lenvatinib or sorafenib in first-line uHCC (HR 0.79; p=0.018). 36-mo OS: 38% vs 24% ORR: 36% vs 13% Median DoR: 30.4 mo vs

Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers ESMO Open ESMO - Eur. Oncology. The results of bemarituzumab phase 3 studies are awaited.OncoAlert OncoDaily sciencedirect.com/science/articl…

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial -The Lancet Oncology thelancet.com/journals/lanon…

Clinical Implications of a Large-Scale Voluntary Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary Results | JCO Oncology Practice ascopubs.org/doi/10.1200/OP…

New The Lancet - Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial thelancet.com/journals/lance… #GITwitter #MedTwitter #OncTwitter

‼️🚨Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer a new SOC ⁦NEJM⁩ nejm.org/doi/full/10.10…